Protonix News and Research

RSS

Teva comments on Lovenox’s patent infringement lawsuit

Teva Pharmaceutical Industries Ltd. commented today on the patent infringement lawsuit filed by Momenta Pharmaceuticals, Inc. and Sandoz Inc.

3 Dec 2010

Teva board authorizes $1 billion share repurchase program

Teva Pharmaceutical Industries Ltd. announced today that its Board of Directors has authorized the Company to repurchase (including through one or more subsidiaries) up to an aggregate of $1 billion of its ordinary shares/ADRs over the next 12 months.

1 Dec 2010

Teva presents QNAZE Phase III study results for SAR at ACAAI Meeting

Teva Pharmaceutical Industries Ltd. today announced results from a Phase III study of QNAZE (beclomethasone dipropionate [BDP]) HFA, a nasal aerosol corticosteroid in development for the treatment of seasonal allergic rhinitis (SAR), that demonstrated significantly greater symptom relief compared with placebo.

15 Nov 2010

Teva hosts Respiratory Opportunity Meeting for financial community

Teva Pharmaceutical Industries Ltd. today hosted its Respiratory Opportunity Meeting for the financial community in New York, featuring in-depth presentations on Teva's current and future respiratory growth strategy.

8 Nov 2010

Teva third quarter net sales increase 20% to $4.3 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended September 30, 2010.

2 Nov 2010

Intellipharmaceutics announces FDA acceptance to file ANDA for Protonix generic version

Intellipharmaceutics International Inc. today announced that the Food and Drug Administration (FDA) has accepted for filing its abbreviated new drug application (ANDA) for a generic version of Protonix (delayed release pantoprazole sodium).

18 Oct 2010

Teva Pharmaceutical announces new data from PreCISe study

Teva Pharmaceutical Industries Ltd. today announced new data from the five-year extension of the PreCISe study demonstrating that earlier initiation of treatment with Copaxone (glatiramer acetate injection) in patients presenting with first signs of multiple sclerosis (MS), provided greater effects in delaying conversion to clinically definite MS (CDMS) compared to later treatment initiation after diagnosis of CDMS or after three years on the study.

18 Oct 2010

Neuroprotective properties of laquinimod for RRMS presented at 26th ECTRIMS Congress

Teva Pharmaceutical Industries Ltd. and Active Biotech announced today that data providing further evidence of the neuroprotective properties of laquinimod in animal studies were presented at the 26th Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Gothenburg, Sweden.

15 Oct 2010

Bristol-Myers, Otsuka launch My SPRYCEL Support program to assist patients with CML

Bristol-Myers Squibb Company and Otsuka Pharmaceutical Co., Ltd. today announced the launch of My SPRYCEL (dasatinib) Support, a useful resource to assist adult patients with chronic myeloid leukemia (CML) who are taking SPRYCEL.

15 Oct 2010

FDA issues Complete Response Letter for Teva's Neutroval BLA

Teva Pharmaceutical Industries Ltd. announced today that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter for the Biologic License Application (BLA) for Neutroval™ (granulocyte colony-stimulating factor) for the reduction in the duration of severe neutropenia and the incidence of febrile neutropenia in patients treated with established myelosuppressive chemotherapy for cancer.

1 Oct 2010

Teva Pharmaceuticals, OncoGenex initiate SYNERGY Phase 3 trial to evaluate custirsen

Teva Pharmaceuticals Industries Ltd. and OncoGenex Pharmaceuticals, Inc. announced today the initiation of SYNERGY, a global Phase 3 trial evaluating custirsen (also known as OGX-011/TV-1011) as first line therapy for the treatment of castrate-resistant prostate cancer (CRPC).

30 Sep 2010

Teva asserts infringement of 4 COPAXONE-related patents by Mylan, files complaint in U.S. District Court

Teva Pharmaceutical Industries Ltd. announced today it has filed a complaint in the U.S. District Court for the Southern District of New York against Mylan asserting infringement of four patents related to the characterization of COPAXONE® (glatiramer acetate injection). The latest of these patents expires in February 2020.

22 Sep 2010

Multinational study demonstrates positive effects of laquinimod in patients with RRMS

Teva Pharmaceutical Industries Ltd. and Active Biotech today announced results from a 36-week active extension study evaluating two doses of laquinimod, an investigational, once-daily oral immunomodulator, for the treatment of relapsing remitting multiple sclerosis.

21 Sep 2010

Teva completes ratiopharm acquisition

Teva Pharmaceutical Industries Ltd. announced today that it has completed the acquisition of ratiopharm, Germany's second largest generics producer. Following the acquisition, Teva will be the number one generic company in Europe, holding the leading market position in ten countries, as well as ranking in the top three in seven additional countries. In addition, the transaction will significantly increase Teva's sales in Canada.

10 Aug 2010

TEMPO study recommends early administration of Azilect in PD patients

Teva Pharmaceutical Industries Ltd. and H. Lundbeck A/S (Lundbeck) today announced newly published long-term data on Azilect(rasagiline tablets) from the TEMPO study and its open-label extension. The findings confirm the long-term efficacy, safety and tolerability of Azilect® in patients with Parkinson's disease (PD) and further demonstrate the benefits obtained with early treatment initiation. The data was published in the June 2010 issue of the International Journal of Neuroscience.

6 Aug 2010

European Commission grants Teva approval for acquisition of ratiopharm

Teva Pharmaceutical Industries Ltd. announced today that the Company received approval from the European Commission to proceed with its acquisition of ratiopharm.

4 Aug 2010

Teva Respiratory reports positive results from BDP HFA Nasal Aerosol Phase III trial in seasonal allergic rhinitis

Teva Respiratory today announced positive results from a Phase III trial evaluating the efficacy and safety of beclomethasone dipropionate (BDP) hydrofluoroalkane (HFA) Nasal Aerosol in the treatment of seasonal allergic rhinitis (SAR). The study met all efficacy endpoints, demonstrating a statistically significant benefit as compared to placebo. Furthermore, the safety profile of BDP HFA Nasal Aerosol was similar to placebo.

29 Jul 2010

Sun Pharma reports first-quarter fiscal 2011 results

Sun Pharmaceutical Industries Ltd. reported numbers for the quarter ending June 30, 2010.

28 Jul 2010

Teva second-quarter net sales increase 12% to $3.8 billion

Teva Pharmaceutical Industries Ltd. today reported results for the quarter ended June 30, 2010.

27 Jul 2010

Teva comments on FDA's approval of generic Lovenox injection

Teva Pharmaceutical Industries Ltd. commented today on the U.S. Food and Drug Administration's response to a citizen petition questioning the approval criteria for a generic Lovenox (enoxaparin sodium) injection and its subsequent approval of another generic filer's Abbreviated New Drug Application.

26 Jul 2010